Zdrowie i gospodarka · 05/06/2023
FDA Announces Revised Draft Guidance for Interstitial Cystitis/Bladder Pain Syndrome Treatment
The FDA has released a revised draft guidance for industry, outlining recommendations for developing drugs to treat interstitial cystitis/bladder pain syndrome, replacing a previous draft guidance issued in 2019.
Source: Federal Register — Food and Drug AdministrationOpen original release →